Podcast: Play in new window | Download (Duration: 5:29 — 1.3MB)
Subscribe: Spotify | Email | RSS | More
Original Podcast with clickable words
https://tinyurl.com/y4jz67yd
Doubts cast on vaccine efficacy in the elderly.
Amhras caite ar éifeachtacht vacsaíne i gcás seandaoine.
Authorities in Germany are recommending that the AstraZeneca company Covid-19 vaccine be given only to people between the ages of 18 and 64.
Tá sé á mholadh ag na húdaráis sa Ghearmáin gan vacsaín covid 19 an chomhlachta AstraZeneca a thabhairt ach do dhaoine idir 18 agus 64 bliain.
According to the German health department, there is still insufficient information on the effectiveness of the vaccine in people over 65.
Dar le roinn sláinte na Gearmáine nach bhfuil dóthain faisnéise ar fáil fós faoi éifeachtacht na vacsaíne i measc daoine os cionn 65.
The European Medicines Agency, a European Union institution, is to announce a decision tomorrow on approving the AstraZeneca vaccine in EU member states.
Tá Gníomhaireacht Leigheasra na hEorpa, foras de chuid an Aontais Eorpaigh, le cinneadh a fhógairt amárach faoi vacsaín lucht AstraZeneca a cheadú i mballstáit an Aontais.
The company denied earlier this week that the vaccine is less effective for people over 65.
Shéan an comhlacht i dtús na seachtaine nach bhfuil an vacsaín chomh héifeachtach sin i gcás daoine os cionn 65.
They claimed that there is not as much information about the vaccine as there is about other body vaccines as those others were given to the elderly before theirs.
Mhaígh siad nach bhfuil an oiread céanna faisnéise ann faoin vacsaín agus atá faoi vacsaíní comhlachtaí eile mar gur tugadh na cinn eile sin do sheandaoine roimh an gceann sacusan.
However, the information suggests that the vaccine is as effective in the elderly as it is in the young.
Ina dhiadh sin féin, a dúirt siad, léiríonn a bhfuil ann dfhaisnéis go bhfuil an vacsaín chomh héifeachtach i measc seandaoine agus atá sí i gcás daoine óga.
Earlier today, Pfizer-BioNTech said that their vaccine is capable of overcoming the new variants of the recently emerged coronary virus.
Níos túisce inniu, dúirt lucht Pfizer-BioNTech go bhfuil a vacsaín siúd in acmhainn na hathraithigh nua ar an gcoróinvíreas atá tagtha chun cinn le deireanas a chloí.